On August 25, 2022 Genexine (KOSDAQ: 095700), a publicly traded, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, reported that late-breaking results from the Phase 2 clinical trial study of its therapeutic DNA vaccine GX-188E in combination with MSD’s (Merck & Co., Inc., Rahway, NJ., USA) anti-PD-1 therapy, KEYTRUDA (pembrolizumab), were selected for an oral presentation at the 2022 European Society for Medical Oncology Congress which is being held from September 9-13 in Paris, France (Press release, Genexine, AUG 25, 2022, View Source [SID1234618676]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details:
Oral Presentation
Title
Efficacy and safety of GX-188E, a therapeutic DNA vaccine, combined with pembrolizumab in HPV 16- and/or 18- positive advanced cervical cancer (Phase II): Safe & effective both in PD-L1 positive and negative
Date and Time
Sat, 10th September 2022 at 08:35~08:40 AM CEST
Session
Mini Oral Session 1: Gynaecological cancers (#LBA32)
Location
7.2.E – Évry Auditorium
"We are delighted to have been invited to present these very important clinical results of Genexine’s innovative immuno-oncology DNA vaccine, GX-188E in combination with pembrolizumab, an approved immune checkpoint inhibitor," said Neil Warma Genexine’s CEO. "With the completion of this Phase 2 clinical trial, we plan to submit for conditional approval to the Korean MFDS (Ministry of Food and Drug Safety). We believe this could offer hope for a new immunotherapy treatment option to patients with recurrent/metastatic end-stage cervical cancer."
KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.